Royalty Report: Drugs, Pain, Biotechnology – Collection: 2364

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pain
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2364

License Grant
The Company acquired an exclusive license to a technology providing for an efficient isolation of the baine from raw poppy.  The primary derivative of the baine is oxycodone, an API (active pharmaceutical ingredients) used in pain management pharmaceutical products (the Thebaine Technology and collectively with the Codeine Technology, the Licensed Technologies).
License Property
The Licensed Technologies are novel processes intended to be more efficient and cost effective methods of deriving APIs to be used in the manufacture of finished dosage pain management products by substantially reducing the time and steps required to produce the desired API.
Field of Use
The rights granted apply to pharmaceutical products.

IPSCIO Record ID: 26480

License Grant
The Company acquired an exclusive license to a patented technology for the efficient manufacture of codeine-based APIs (active pharmaceutical ingredients) used in pain management pharmaceuticals products (the Codeine Technology).
Field of Use
The Licensed Technology is a novel processes intended to be more efficient and cost effective methods of deriving APIs to be used in the manufacture of finished dosage pain management products by substantially reducing the time and steps required to produce the desired API.

IPSCIO Record ID: 253953

License Grant
The Parties have entered into a Settlement Agreement.  As a result of and pursuant to the Settlement Agreement,  the Licensor grants a limited, non-exclusive,  non-transferable license of limited duration under the Patent to make, have made, use, offer to Sell and Sell, in the United States, up to an aggregate of 800,000 bottles, subject to the reductions set forth below, of the generic versions of 10 mg, 15mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg dosage strengths of the Licensee Products, allocated among the dosage strengths.
License Property
The patent is relating to and protecting controlled-release oxycodone products, including the product OxyContin®, a controlled-release oxycodone product marketed and sold under NDA No. 20-553 OxyContin®.
Field of Use
Licensee is a specialty branded pharmaceutical company.  The product is for the management of pain with opioid analgesics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.